From the *University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY

the †Cystic Fibrosis Community Member, Boston, MA

the ‡Cystic Fibrosis Foundation, Bethesda, MD

the §Synspira Therapeutics, Inc., Framingham, MA.

Received June 7, 2022; accepted August 26, 2022.

D.B. receives compensation as a member of the Scientific Advisory Board of Synspira Therapeutics, Inc. and holds stock as a member of the Board of Directors; Synspira Therapeutics is developing a PERT. J.F.B. is a consultant for Synspira Therapeutics, Inc. and is a member of the Cystic Fibrosis Foundation Community Voice. E.A. is an employee of the Cystic Fibrosis Foundation. D.G. is an employee of Synspira Therapeutics, Inc.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal’s Web site (www.jpgn.org).

Address correspondence and reprint requests to Drucy Borowitz, MD, Emeritus Professor of Clinical Pediatrics, Jacobs School of Medicine and Biomedical Sciences, 1001 Main Street, 5th Floor, Buffalo, NY 14203 (e-mail: [email protected]).